CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to understand the cardiotoxic effects of combining Doxorubicin and trastuzumab in breast cancer treatment. It focuses on identifying circulating microRNAs as potential biomarkers and investigating their release mechanisms to mitigate drug-induced heart damage.
Combination of Doxorubicin (Dox) and the monoclonal antibody trastuzumab (Trz) is being effectively used against breast cancer, but associated with high incidence of cardiotoxicity.
The mechanisms of Dox+Trz induced synergic cardiotoxicity are still unclear.
Recently the activation of the microRNA 146a has been shown to have a role in the synergistic effect of Dox and Trz cardiotoxicity.
MicroRNAs (miRNA) are ~22 nucleotides long non-coding RNAs regulating complex cellular processes.
MiRNAs can…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
